

Justyna Kiszalkiewicz¹, Wojciech J. Piotrowski², Ewa Brzezińska-Lasota¹

¹Department of Molecular Bases of Medicine, 1st Chair of Internal Medicine, Medical University of Lodz, Poland

²Department of Pneumology and Allergy, 1st Chair of Internal Medicine, Medical University of Lodz, Poland

Signaling pathways and their miRNA regulators involved in the etiopathology of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP)

Abstract

Idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) belong to heterogenic group of interstitial lung diseases (ILD). For the reason that this group of diseases present with complex clinical non-specific features, they represent a diagnostic and therapeutic challenge. In this review we focus on several crucial signaling pathways participating in inflammation, fibrosis and EMT processes, so important in the course of ILD: TNF- α /NF κ B, TGF- β /SMAD, Wnt- β -catenin and PI3K-Akt signaling. Moreover, this review summarizes the role of selected signaling pathways and some miRNAs which are their regulators during development and progression of IPF and HP. Recent advances indicate the potential role of miRNAs as a molecular markers differentiating clinical course of ILD.

Key words: idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, molecular markers, pathogenesis, signaling pathways
Adv. Respir. Med. 2017; 85: 169–178

Introduction

Idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) belong to heterogeneous group of interstitial lung diseases (ILD), where profibrotic/antifibrotic as well as proinflammatory/anti-inflammatory imbalance is postulated. However, exact etiology of these diseases is not fully understood, the alveolar epithelial cell injury and dysregulated repair processes are suggested [1–3].

IPF is categorized as one of the most common (17–86%), chronic, progressive lung disease, with low survival rate (median survival 3–5 years after diagnosis), and is currently untreatable [4–6]. Recent studies have confirmed two major risk factors in IPF development: (1) environmental factors (e.g., cigarette smoking, viral infections), (2) genetic factors (e.g., allelic variants of *VEGF*, *TGF- β* , *MUC5B*, telomerase complex: *telomerase reverse transcriptase* (*TERT*), *telomerase RNA* (*TR* or *TERC*) [7–9]. As

so far, several important processes involved in IPF are postulated: recruitment of inflammatory cells, deposition of extracellular matrix, accumulation of fibroblasts [2, 10] or activation of epithelial mesenchymal transition (EMT) [11].

HP belongs to a group of immunologically mediated lung diseases. Repeated exposition and inhalation of wide variety of antigens, such as: bacteria (e.g., *Saccharopolyspora rectivirgula*), fungi (e.g., *Trichosporon cutaneum*) [12], animal proteins (mostly avian) [13], chemicals (e.g., di-isocyanates) [14] and incites hypersensitivity reaction of lung with granulomatous inflammation in genetically predisposed subjects [15]. Three key clinical forms of HP are distinguished: acute, subacute and chronic with frequent overlapping of these three forms [3]. Polymorphisms of transporters associated with antigen processing (TAP) genes are found in HP patients [16]. The essential reason of HP is coexistence of genetic/environmental factors which are able to stimulate

Address for correspondence: Ewa Brzezińska-Lasota, Department of Molecular Bases of Medicine, Medical University of Lodz, Pomorska 251, 92–213 Lodz, Poland, tel: +48 42 272 57 91, e-mail: ewa.brzezińska@umed.lodz.pl

DOI: 10.5603/ARM.2017.0029

Received: 17.11.2016

Copyright © 2017 PTChP

ISSN 2451–4934

an exaggerated immune reaction resulting in lung inflammation. Following the immunopathological changes induced in lung cells, the fibroblast expansion and extracellular matrix (ECM) accumulation may occur [2].

Reassuring, chronic inflammation and EMT are recognized as two key pathological processes involved in IPF and HP development where several signaling pathways (e.g., TNF- α /NF κ B, TGF- β /SMAD, Wnt- β -catenin) are activated. Additionally, the role of many different classes of miRNAs, which may regulate the mentioned signaling pathways *via* gene expression at post-transcriptional level has been recognized.

In this review the authors discussed the role of selected signaling pathways and some miRNAs as their regulators in the development and progression of IPF and HP.

Signaling pathways involved in IPF and HP development

Inflammation

Inflammation is postulated as an initial and a critical factor in HP and in IPF is rather a secondary process associated with fibrosis. For a long time it has been assumed that inflammation plays a direct role in pathogenesis of IPF. However, lung cells derived from IPF patients reveal high expression levels of genes involved in proliferation, migration, oxidative stress and remodeling. Several lines of evidence suggests that inflammation may play a key role in acute exacerbation of IPF, but not in chronic disease itself [17]. Additionally, lack of response to long-term anti-inflammatory treatment suggests that epithelial pathway (with cytokine/growth factor releasing and fibroblast migration) may be possible process in pulmonary fibrosis [2]. Selman et al. [2] proposed two different routes for pulmonary fibrosis development: a) the inflammatory pathway and b) the epithelial pathway. Based on the studies on human IPF and animal models of pulmonary fibrosis, five possible hypotheses for the pathogenesis of IPF have been proposed, underlining the controversial role of inflammation: 1) direct inflammation hypothesis, 2) matrix hypothesis in which inflammatory mediators are released under distant injury *via* extracellular matrix, 3) growth factor receptor hypothesis, where GFRs release the inflammatory cascade activation, 4) plasticity hypothesis based on EMT and multifarious interactions between inflammatory mediators and GFs and other key factors which facilitate the fibrotic phenotype, 5) vascular hypothesis which suggest that endothe-

lial injury activates the inflammatory cascade leading to fibrosis [17, 18].

In HP, the dispersed antigens provoke a hypersensitivity reaction with granulomatous inflammation in the distal bronchioles and alveoli [13]. Characterized as bronchiolocentric granulomatous lymphocytic alveolitis may develop to fibrosis in advanced stage of HP [3]. In HP, the exposed antigens act as specific inducing factors. Immediately after antigen challenge, an immunological response — followed by production of IL-1 and TNF- α by macrophages — takes place [15]. Secretion of IL-1 and TNF- α may lead to adhesion molecule expression on leukocytes and endothelial cells. What is more, macrophages secrete IL-8, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1a, and RANTES that act as chemotactic factors for a variety of cells [19]. The exact mechanism of the disease remains unclear. It is suggested that tolerance may be mediated by regulatory T cells (Treg), a unique population of CD4⁺ T cells that play a pivotal role in the maintenance of the balance between the tissue-damaging and protective effects of the immune response [20]. The disease chronicity depends on immunopathological processes. Patients with chronic HP show an decrease of CD4⁺ T cells and exhibit skewing toward Th2 immunological activity [21]. It was confirmed that most patients have usually a low CD4⁺/CD8⁺ ratios, typically < 1 in BAL — conversely that in sarcoidosis.

TNF- α /NF κ B signaling pathway

Tumor necrosis factor (TNF- α), which activates NF- κ B family of transcription factors, plays an important role in the immune system regulation, influences the expression of cytokines, inducible nitric oxide synthase (iNOS), cyclo-oxygenase 2 (COX-2), growth factors and inhibitors of apoptosis [22]. The activation of NF- κ B dimers occurs by two pathways: classical (canonical) and the alternative (non-canonical) pathway [23]. The common regulatory step in both pathways is activation of I κ B kinase (IKK) complex encompassing catalytic kinase subunits (IKK α and/or IKK β) and the regulatory non-enzymatic scaffold protein NEMO (NF- κ B essential modulator also known as IKK γ). In the absence of TNF- α stimulation, NF- κ B is associated with the inhibitor I κ B in the cytoplasm. Activation of NF- κ B dimers (IKK α and/or IKK β) is due to IKK-mediated phosphorylation-induced proteasomal degradation of I κ B. Therefore, active NF- κ B transcription factor subunits may be relocated to the nucleus and

prompt target genes expression [24, 25]. It was recognized that TNF- α after stimulation may be released by macrophages, T-cells, B-lymphocytes, granulocytes, smooth muscle cells, eosinophils, chondrocytes, osteoblasts, mast cells, glial cells, and keratinocytes [26]. Recently, genetic studies have showed that polymorphism in TNF- α gene (TNF-308A) is associated with high TNF- α production *in vitro*, and this frequency is significantly increased in HP patients [27]. Another study has demonstrated that high expression of TNF- α is associated with a greater risk for developing farmer's lung and pigeon fancier's lung diseases as a form of hypersensitivity pneumonitis [13]. Previous studies in human and on animal model have confirmed that NF- κ B plays a vital role in inflammatory process in lung and in the pathogenesis of pulmonary fibrosis [28, 29]. In BLM (bleomycin) mice model lung inflammation and pulmonary fibrosis were significantly relieved by GLP-1 treatment, possibly through inactivation of NF- κ B [29]. Current data have demonstrated that NF- κ B has both pro- and anti-inflammatory functions, permitting NF- κ B to play a role both in the initiation and in the resolution of inflammation. Due to the fact that NF- κ B takes part in the inflammatory response, the therapeutic strategies to block NF- κ B signaling and arrest the disease process may be developed in the future [30].

EMT process

It is marked that the disruption of alveolar epithelium integrity with the presence of enhanced migration of fibroblasts into the alveolar spaces may be involved in epithelial pathway of IPF pathomechanism [2]. The presence of subepithelial fibroblast and myofibroblast loci in extracellular matrix followed by the abnormal remodeling of the ECM is considered a prognostic factor in IPF [31]. Type 2 EMTs is associated with wound healing, tissue regeneration, and organ fibrosis. In recent years IPF pathomechanism has been recognized rather as a disease characterized by epithelial injury, abnormal epithelial healing and enhanced fibrotic response than the predominantly inflammatory lung disease. In the pathological background of IPF, epithelial microinjuries, increased inflammatory and/or pro-fibrotic cytokines followed by fibroblast accumulation leads to fibrotic lesion and EMT [32–34]. Therefore, it is postulated that excessive accumulation of fibroblasts generates abnormal epithelial-mesenchymal interactions due to EMT. In addition, the recent study of Yasui *et al.* [35] has shown that EMT is involved in hypersen-

sitivity pneumonitis. Based on animal model, authors have confirmed the correlation between the increased percentage of EMT cells and IL-13 and TGF- β 1 mRNA expression, as well as an increased amount of collagen [35].

In human and rat alveolar epithelial cells and in epithelial cell lines it has been confirmed that EMT may be activated by the action of some important pathways, such as TGF- β /SMAD or Wnt/ β -catenin signaling [9].

TGF- β /Smad signaling pathway

Many studies have demonstrated that TGF- β /Smad (*transforming growth factor- β /Smad*) is a pleiotropic signaling pathway which play a crucial role in inflammation, wound healing and fibrotic processes [9]. It is also considered as a great inducer of ECM deposition and EMT process in tissue fibrosis *via* Smad-dependent cascade [18, 35, 36]. There are irrefutable evidences that Smad2 and Smad3 play distinct roles in TGF- β /Smad signaling and their expression is different in epithelial cells and fibroblasts. During fibrosis, in adult fibroblast, TGF- β /Smad signaling pathway is working under Smad3 but not Smad2 [37]. It was suggested that TGF- β can suppress Smad 3/4 action via the overexpression of Smad 7 [38]. Smad 7 can act as an inhibitor by suppressing the phosphorylation of Smad 2 and Smad 3 via ubiquitination by Smurf2 ubiquitin-protein ligase. This process contributes to the degradation of the TGF- β R1 and R2 receptor complex, inhibiting TGF- β signaling as a final consequence [39]. It is also suggested that Smad 7 gene expression influences lung airway remodeling and lung injuries, leading to fibrosis through regulating the magnitude of TGF- β signaling [40].

It is documented that during interstitial disease development, the exposure of the airways to allergens results in the inflammatory response with the secretion of TGF- β and other inflammatory mediators. In consequence, the thickening of the lung cell membranes and lung damage may occur. In the next step, lung repair mechanism associated with the secretion of some mediators stimulates migration and proliferation of fibroblasts. Transformation to myofibroblast phenotype is started, which leads to pulmonary fibrosis, impedes gaseous exchange in the lungs and results in the respiratory failure [41].

Therefore, it is accepted that TGF- β is a main cytokine responsible for tissue regeneration, scarring and remodeling. The fibroblasts which are presented in a wound, as specialized myofibroblasts, may activate extracellular matrix *via*

elevated levels of α -smooth muscle actin (SMA), connective tissue growth factor (CTGF), and secretion of matrix proteins, such as collagen and fibronectin [42]. Activation of TGF- β /SMAD signaling pathway may also occur in non-canonical way. TGF- β can activate all three known MAPK pathways: extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK) and c-Jun-N-terminal kinase (JNK). These ways of signaling further regulate Smad-independent TGF- β responses. Moreover, p38 MAPK [43] and JNK [44] usually increase TGF- β /Smad responses. In addition to Smad and MAPK, TGF- β has been shown to activate PI3 kinase/Akt, Rho GTPase pathways and cooperate with Wnt and Notch [45]. The latest data show that pro-fibrotic effects of TGF- β are mediated through upregulation of its downstream effector Connective Tissue Growth Factor (CTGF). TGF- β -induced expression of CTGF stimulates myofibroblast differentiation and collagen synthesis [46]. On the other hand, CTGF enhances the activity of TGF- β leading to the increased binding to T β RI and T β RII [47]. The CTGF expression was related to fibroblast proliferation, cellular adhesion, angiogenesis, and synthesis of ECM [48]. It is expressed in various types of cells, including: epithelial, vascular smooth muscle, and fibroblasts also in lung [48, 49]. It was documented that higher CTGF level contributes to expression of α -smooth muscle actin (α -SMA) and the myofibroblast phenotype in tissue repair or development of connective tissues [50, 51]. What is more, CTGF appears to play a critical role in mediating many important fibroproliferative effects of TGF- β , including the pathogenesis of fibrotic disorders [52–54]. On the other hand, other pro-inflammatory cytokines, e.g., TNF- α or IFN- γ , are expressed in macrophages during the wound healing. They suppress matrix genes activities and act as antifibrotic factors [42]. Reassuring, biological effects of TGF- β in lung epithelium include control of airway remodeling, supervision of bronchial fibrosis and wound healing [55].

The activity of signaling pathways induced by TGF- β depends on cell type, cell differentiation, interaction with other signaling pathways (PI3K/Akt or Wnt/ β -catenin) and individual genetic predispositions.

In relation to therapy glucocorticoids (GCs) are among the first-line therapeutics in inflammatory diseases. They are responsible among others for inhibition of phagocytosis and lysosomal breakdown. They can also reduce the number of lymphocytes, eosinophils, and monocytes [56].

It has been documented that the SNP polymorphisms in NR3C1 gene (glucocorticoid receptor) don't influence the secretion of many factors, such as: TGF- β , GM-CSF, VEGF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-12, IL-13, IL-16, IL-17. On the other hand, in contrary, the study carried out by Panek *et al.* [56], has documented that SNPs in NR3C1 gene intensify non-sensitivity to GCs in asthmatic patients. It should be emphasized that Tth111I and N363S polymorphisms also significantly modulate the level of TGF- β 1 in patients with asthma, who have been treated with GCs.

PI3K-Akt signaling pathway

It is commonly known that PI3K/Akt (*phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog 1*) signaling pathway regulates cell growth, proliferation and apoptosis. In lung fibrosis in IPF patients, the PI3K/Akt *via* Akt is abnormally activated under mechanisms modulating the activity of the PI3K-AKT-FOXO3a axis, while PTEN – the main inhibitor of PI3K/Akt signaling — is downregulated [9]. The mechanism of fibrosis regulation *via* PI3K/Akt is not fully understood but it has been recognized that during tissue repair, overgrowth of fibroblasts and type I collagen — as a complex with α 2 β 1 integrin — are eliminated by apoptosis, in response to collagen matrix contraction. It has been recognized that PTEN which is activated during collagen matrix contraction, stimulates fibroblast apoptosis. Enhanced Akt activation decreases PTEN level and alters fibroblast survival. It was confirmed on *in vitro* model, where PTEN null fibroblasts presented enhanced level of Akt phosphorylation and therefore resistance to collagenmatrix contraction-induced apoptosis [57]. Moreover, FOXO3a — one of the target gene for Akt — is recognized as a strong inhibitor of cell cycle and apoptosis. Therefore, FOXO3a deficiency could protect IPF fibroblasts from apoptosis and enhanced fibrosis. What is more, in regulation of fibrosis process many interactions with other signaling pathways, such as TGF- β /Smad, MEK/ERK or VEGF, Jak/STAT, have been documented. It should be pointed that this complex regulation of fibrosis with many interacting signaling pathways involved, suggests that single molecules of the mentioned paths may not be accepted as good molecular targets for therapy.

Wnt/ β catenin signaling pathway

The Wnt-catenin signaling pathway regulates many biological processes, such as: fate determination, motility, polarity, primary axis formation




Figure 1. The proposal of a crosstalk between signaling pathways involved in EMT process. Abbreviations; TGF- β — transforming growth factor- β ; Smad 2 — mothers against decapentaplegic homolog 2 protein; Smad 3 — mothers against decapentaplegic homolog 3 protein; Smad 4 — mothers against decapentaplegic homolog 4 protein; Wnt — wingless/integration signaling; Dsh — phosphoprotein Dishevelled; GSK3 — glycogen synthase kinase 3; TCF/LEF1 — cell factor/lymphoid enhancing factor; GF — growth factors; PI3K — Phosphoinositide 3-kinase; Akt — Protein kinase B mTOR — mechanistic target of rapamycin

and carcinogenesis. Recent reports have shown that deregulated Wnt-catenin signaling has important negative consequences in embryonic development [58].

In respiratory epithelial cells, the Wnt/ β -catenin signaling pathway is necessary for lung branching and distal airway cell specification [59, 60]. Lately, it has been confirmed that in lung biopsies from IPF patients, high activation of the canonical Wnt/ β -catenin signaling pathway is associated with tissue repair and fibroblast activation [61, 62].

Based on the above mentioned data, it is thought that Wnt/ β -catenin signaling plays an important role in many pathological processes in lung, such as: inflammation, remodeling and fibrosis. Recently, it has been also documented that Wnt/ β -catenin signaling is involved in the induction of EMT, an important step in fibrosis development [63]. The study of Königshoff *et al.* [64] confirmed significantly increased expression of Wnt1, 3a, 7b and 10b, Fzd2, Fzd3, β -catenin, and LEF1 in IPF patients. What is more, authors have demonstrated that Wnt1, Wnt3a, β -catenin, and GSK-3 β are localized in alveolar and bronchial epithelium [64]. Especially Wnt3a is

recognized as a promotor of lung epithelial cell proliferation and myofibroblast activation [64]. Interestingly, the increased level of β -catenin and Wnt/ β -catenin signaling pathway promotes fibroblast migration and proliferation and is associated with ventilator-induced pulmonary fibrosis in previously healthy persons [65]. These data indicate that activation of β -catenin may be a common feature of lung fibrosis, including pathological process in IPF.

It is also known that Wnt/ β -catenin signaling pathway may link the IPF progression with other signaling pathways as a special cross-talk between them. Mainly TGF- β could trigger Wnt/ β -catenin signaling pathway and initiate the cellular matrix accumulation. In Wnt/ β -catenin signaling, the regulation of fibrosis, the nuclear translocation of β -catenin *via* the phosphorylation of ERK1/2 and suppression GSK-3b activity seem to be crucial [66]. The proposal crosstalk between signaling pathways involved in EMT process is shown in Figure 1.

miRNA a potential gene expression regulators

It is well identified that miRNAs are able to post-transcriptionally regulate gene expression

Table 1. Important miRNAs regulating the selected signaling pathways in inflammation process in IPF and HP

miRNA	Target	Function	Disease	Process	Reference
miR-146	IL-8	In human lung alveolar epithelial tumor A549 cells miR-146a negatively regulates the release of IL-8 and RANTES	HP?	inflammation	[71]
miR-155	<i>NF-κB</i> <i>IFN-γ</i>	In human mesangial cells, <i>IFN-γ</i> and <i>TNF-α</i> induce miR-155 expression and regulate inflammatory and immune responses,	HP?	inflammation	[74]

in almost all aspects of physiological conditions, such as: cell differentiation, cell growth, mobility and apoptosis. Therefore, miRNAs are noted as important factors involved in the development of many human diseases. Many classes of miRNAs exhibiting abnormal expression have been recognized as therapeutic targets.

It is noteworthy that miRNAs can be detected in various biological materials, such as: tissue, blood, serum, plasma, body fluids. Current studies have confirmed that exosomes are “bioactive vesicles” that promote intercellular communication and immunoregulatory processes by transporting molecules between cells [67, 68]. What is more, exosomal miRNAs (by being packaged in lipid vesicles) are protected against degradation and can be functionally delivered to target cells.

miRNAs have been revealed to be expressed in a tissue-specific and developmental stage-specific manner [69]. Also the lung has been shown to have a very specific miRNA expression profile. It has been shown that some miRNAs have characteristic lung specific expression profile. For example, these that participate in biological processes in the lungs, i.e., miR-155, miR-26a, let-7, miR-29, miR-15/miR-16, miR-223, miR-146a/b and the miR-17-92 cluster are involved in homeostasis and in the lung development [70]. Other, like miR-146a/146b [71], miR-155 [72] are important in pulmonary inflammation. All mentioned miRNAs may show up/down regulation in lung. Moreover, it is documented that smoking also influences miRNA expression levels. Expression profiling study in the rats exposed to environmental cigarette smoke revealed 24 downregulated miRNAs (especially let-7 family, miR-10, -26, -30, -34, -99, -122, -123, -124, -125, -140, -145, -146, -191, -192, -219, -222, and -223) when compared to control group [73]. In the respiratory system, miRNAs are important in normal pulmonary development and lung homeostasis. Recent studies have also documented that altered miRNAs expression profiles may be related to pathological processes within the lung, such as inflammatory diseases or lung fibrosis.

Many data have demonstrated that miRNAs are involved in the regulation of adaptive immune system: development, differentiation of B and T cells, proliferation of monocytes and neutrophils, antibody production or release of inflammatory mediators. They may work in the negative feedback regulation of inflammation following activation by the innate immune system. In IPF and HP diseases, miRNAs have been recognized as negative regulators of many signaling pathways involved in inflammation process (Table 1).

Also, miRNA dysregulation has been recognized in fibrotic disorders, as regulators of tissue injury and fibrosis, and especially as EMT controlling factors in IPF and HP (Table 2).

Interestingly, the special attention has focused on significance of miR-21 in pulmonary fibrosis. The study on animal model has confirmed that miR-21 is upregulated in the lungs of mice with bleomycin-induced fibrosis. Moreover, miR-21 has been shown to be upregulated also in the lungs of patients with idiopathic pulmonary fibrosis, under pro-fibrogenic activity of TGF-β [81]. Additionally, let-7d has been recognized as significantly decreased in idiopathic pulmonary fibrosis, which correlates with increased collagen deposition during EMT in mouse lung [76]. Also miR-155 is involved in both inflammatory and pulmonary fibrosis [81]. Functions of the mentioned miRNAs are summarized in Tables 2 and 3.

Conclusions

Our review summarizes the current knowledge on important signaling pathways involved in the pathogenesis of IPF and HP, with an emphasis on two important processes, i.e., inflammation and EMT. We underline a fundamental role of some miRNAs which have the ability to modulate multiple genes and pathways. In recent years there has also been an explosion of reports on miRNA involvement in lung diseases, including interstitial lung diseases (ILD), which may have diagnostic and future therapeutic value. We focus

Table 2. Important miRNAs regulating the selected signaling pathways in EMT process in IPF and HP

miRNA	Target	Function	Disease	Process	Reference
miR-424	Smurf2	Enhances a-SMA expression, regulates the myfibroblast differentiation during EMT by increasing the activity of TGF- β pathway	IPF	EMT	[75]
let-7d	HMGA2 TGF- β 1	Antifibrotic agent Increases the collagen deposition during EMT	IPF	EMT	[76]
miR-326	TGF- β Smad 7	Fibrotic agent	IPF	EMT	[77]
miR-154	FZD4	Promotes proliferation and migration in lung fibroblast	IPF	EMT	[78]
miR-375	FZD8	regulates AEC trans-differentiation through the Wnt/ β -catenin pathway	IPF	EMT	[79]
miR-199a	TGF- β 1	Pathogenic activation of fibroblast	IPF	EMT	[80]

Table 3. Important miRNAs regulating the selected signaling pathways in both inflammation and EMT processes in IPF and HP

miRNA	Target	Function	Disease	Process	Reference
miR-21	Smad7	Inhibits pro-fibrogenic activity of TGF- β pathway in fibroblasts	IPF	EMT	[82]
	IL1- β	miR-21 acts as an anti-inflammatory agent within a negative regulatory loop: NF- κ B activity is necessary for miR-21 induction, but by targeting PDCD4, miR-21 inhibits NF- κ B and its pro-inflammatory transcriptional targets.	HP?	inflammation	[83]
miR-17~92 cluster	TGF- β	Regulates lung epithelial cell development	IPF	EMT inflammation	[84]
miR-200 family	E-cadherin ZEB1 ZEB2 TGF- β	These miRNAs are regulators/inhibitors of EMT and act to maintain the epithelial phenotype by targeting the expression of the E-cadherin transcriptional repressors, ZEB1 and ZEB2	IPF HP?	Inflammation EMT	[85, 86]




Figure 2. MiRNAs that regulate inflammation, EMT or both processes in ILD pathogenesis

on some miRNAs which control the processes of inflammation (miR-146, miR-155) and EMT (miR-424, let-7d, miR-326, miR-154, miR-375,

miR-199) in lung disorders; especially IPF and HP. MiRNAs that regulate inflammation, EMT or both processes in ILD are shown in Figure 2.

Based on the progress in molecular biology and in the area of understanding of inflammatory and fibrosis processes in lung and other organs, it seems highly likely that studies focused on miRNA role in the pathogenesis of ILD are extremely important and necessary.

Conflict of interest

The authors declare no conflict of interest.

References:

1. Horowitz JC, Thannickal VJ. Epithelial-mesenchymal interactions in pulmonary fibrosis. *Semin Respir Crit Care Med.* 2006; 27(6): 600–612, doi: [10.1055/s-2006-957332](https://doi.org/10.1055/s-2006-957332), indexed in Pubmed: [17195137](https://pubmed.ncbi.nlm.nih.gov/17195137/).
2. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. *Respir Res.* 2002; 3: 3, indexed in Pubmed: [11806838](https://pubmed.ncbi.nlm.nih.gov/11806838/).
3. Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. *Am J Respir Crit Care Med.* 2012; 186(4): 314–324, doi: [10.1164/rccm.201203-0513CI](https://doi.org/10.1164/rccm.201203-0513CI), indexed in Pubmed: [22679012](https://pubmed.ncbi.nlm.nih.gov/22679012/).
4. Coultas DB, Hughes MP. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. *Thorax.* 1996; 51(7): 717–720, indexed in Pubmed: [8882079](https://pubmed.ncbi.nlm.nih.gov/8882079/).
5. Karakatsani A, Papakosta D, Rapti A, et al. Hellenic Interstitial Lung Diseases Group. Epidemiology of interstitial lung diseases in Greece. *Respir Med.* 2009; 103(8): 1122–1129, doi: [10.1016/j.rmed.2009.03.001](https://doi.org/10.1016/j.rmed.2009.03.001), indexed in Pubmed: [19345567](https://pubmed.ncbi.nlm.nih.gov/19345567/).
6. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. *Clin Epidemiol.* 2013; 5: 483–492, doi: [10.2147/CLEP.S54815](https://doi.org/10.2147/CLEP.S54815), indexed in Pubmed: [24348069](https://pubmed.ncbi.nlm.nih.gov/24348069/).
7. Gait R, Maginnis C, Lewis S, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. *Lancet.* 1996; 347(8997): 284–289, indexed in Pubmed: [8569361](https://pubmed.ncbi.nlm.nih.gov/8569361/).
8. Baumgartner KB, Samet JM, Stidley CA, et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 1997; 155(1): 242–248, doi: [10.1164/ajrccm.155.1.9001319](https://doi.org/10.1164/ajrccm.155.1.9001319), indexed in Pubmed: [9001319](https://pubmed.ncbi.nlm.nih.gov/9001319/).
9. Yan Z, Kui Z, Ping Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. *Autoimmun Rev.* 2014; 13(10): 1020–1025, doi: [10.1016/j.aur.2014.08.028](https://doi.org/10.1016/j.aur.2014.08.028), indexed in Pubmed: [25182202](https://pubmed.ncbi.nlm.nih.gov/25182202/).
10. Selman M, King TE, Pardo A, et al. American Thoracic Society, European Respiratory Society, American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med.* 2001; 134(2): 136–151, indexed in Pubmed: [11177318](https://pubmed.ncbi.nlm.nih.gov/11177318/).
11. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. *Fibrogenesis Tissue Repair.* 2012; 5(1): 11, doi: [10.1186/1755-1536-5-11](https://doi.org/10.1186/1755-1536-5-11), indexed in Pubmed: [22824096](https://pubmed.ncbi.nlm.nih.gov/22824096/).
12. Malmberg P, Rask-Andersen A, Höglund S, et al. Incidence of organic dust toxic syndrome and allergic alveolitis in Swedish farmers. *Int Arch Allergy Appl Immunol.* 1988; 87(1): 47–54, indexed in Pubmed: [3170008](https://pubmed.ncbi.nlm.nih.gov/3170008/).
13. Calvert JE, Baldwin CI, Allen A, et al. Pigeon fanciers' lung: a complex disease? *Clin Exp Allergy.* 1999; 29(2): 166–175, indexed in Pubmed: [10051719](https://pubmed.ncbi.nlm.nih.gov/10051719/).
14. May JJ, Stallones L, Darrow D, et al. Organic dust toxicity (pulmonary mycotoxicosis) associated with silo unloading. *Thorax.* 1986; 41(12): 919–923, indexed in Pubmed: [3590053](https://pubmed.ncbi.nlm.nih.gov/3590053/).
15. Bourke SJ, Dalphin JC, Boyd G, et al. Hypersensitivity pneumonitis: current concepts. *Eur Respir J Suppl.* 2001; 32: 81s–92s, indexed in Pubmed: [11816827](https://pubmed.ncbi.nlm.nih.gov/11816827/).
16. Aquino-Galvez A, Camarena A, Montañó M, et al. Transporter associated with antigen processing (TAP) 1 gene poly-

- morphisms in patients with hypersensitivity pneumonitis. *Exp Mol Pathol.* 2008; 84(2): 173–177, doi: [10.1016/j.yexmp.2008.01.002](https://doi.org/10.1016/j.yexmp.2008.01.002), indexed in Pubmed: [18342853](https://pubmed.ncbi.nlm.nih.gov/18342853/).
17. Bringardner BD, Baran CP, Eubank TD, et al. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. *Antioxid Redox Signal.* 2008; 10(2): 287–301, doi: [10.1089/ars.2007.1897](https://doi.org/10.1089/ars.2007.1897), indexed in Pubmed: [17961066](https://pubmed.ncbi.nlm.nih.gov/17961066/).
18. Gibson K, Kaminski N. The mechanisms of idiopathic pulmonary fibrosis: can we see the elephant? *Drug Discovery Today: Disease Mechanisms.* 2004; 1(1): 117–122, doi: [10.1016/j.ddmcc.2004.08.002](https://doi.org/10.1016/j.ddmcc.2004.08.002).
19. Denis M. Proinflammatory cytokines in hypersensitivity pneumonitis. *Am J Respir Crit Care Med.* 1995; 151: 164–169, doi: [10.1164/ajrccm.151.1.7812548](https://doi.org/10.1164/ajrccm.151.1.7812548).
20. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat Immunol.* 2007; 8(2): 191–197, doi: [10.1038/ni1428](https://doi.org/10.1038/ni1428), indexed in Pubmed: [17136045](https://pubmed.ncbi.nlm.nih.gov/17136045/).
21. Barrera L, Mendoza F, Zuñiga J, et al. Functional diversity of T-cell subpopulations in subacute and chronic hypersensitivity pneumonitis. *Am J Respir Crit Care Med.* 2008; 177(1): 44–55, doi: [10.1164/rccm.200701-093OC](https://doi.org/10.1164/rccm.200701-093OC), indexed in Pubmed: [17947613](https://pubmed.ncbi.nlm.nih.gov/17947613/).
22. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends Immunol.* 2004; 25(6): 280–288, doi: [10.1016/j.it.2004.03.008](https://doi.org/10.1016/j.it.2004.03.008), indexed in Pubmed: [15145317](https://pubmed.ncbi.nlm.nih.gov/15145317/).
23. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. *Oncogene.* 2006; 25(51): 6680–6684, doi: [10.1038/sj.onc.1209954](https://doi.org/10.1038/sj.onc.1209954), indexed in Pubmed: [17072321](https://pubmed.ncbi.nlm.nih.gov/17072321/).
24. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. *J Cell Mol Med.* 2004; 8(4): 445–454, indexed in Pubmed: [15601573](https://pubmed.ncbi.nlm.nih.gov/15601573/).
25. Muenchen HJ, Lin DL, Walsh MA, et al. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBAlpha „super-repressor“. *Clin Cancer Res.* 2000; 6(5): 1969–1977, indexed in Pubmed: [10815922](https://pubmed.ncbi.nlm.nih.gov/10815922/).
26. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFalpha in pulmonary pathophysiology. *Respir Res.* 2006; 7: 125, doi: [10.1186/1465-9921-7-125](https://doi.org/10.1186/1465-9921-7-125), indexed in Pubmed: [17034639](https://pubmed.ncbi.nlm.nih.gov/17034639/).
27. Schaaf BM, Seitzer U, Pravica V, et al. Tumor necrosis factor-alpha -308 promoter gene polymorphism and increased tumor necrosis factor serum bioactivity in farmer's lung patients. *Am J Respir Crit Care Med.* 2001; 163(2): 379–382, doi: [10.1164/ajrccm.163.2.2002062](https://doi.org/10.1164/ajrccm.163.2.2002062), indexed in Pubmed: [11179110](https://pubmed.ncbi.nlm.nih.gov/11179110/).
28. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. *J Clin Invest.* 2001; 107(2): 135–142, doi: [10.1172/JCI11914](https://doi.org/10.1172/JCI11914), indexed in Pubmed: [11160126](https://pubmed.ncbi.nlm.nih.gov/11160126/).
29. Gou Si, Zhu T, Wang W, et al. Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. *Int Immunopharmacol.* 2014; 22(2): 498–504, doi: [10.1016/j.intimp.2014.07.010](https://doi.org/10.1016/j.intimp.2014.07.010), indexed in Pubmed: [25111852](https://pubmed.ncbi.nlm.nih.gov/25111852/).
30. Alvira CM. Nuclear factor-kappa-B signaling in lung development and disease: one pathway, numerous functions. *Birth Defects Res A Clin Mol Teratol.* 2014; 100(3): 202–216, doi: [10.1002/bdra.23233](https://doi.org/10.1002/bdra.23233), indexed in Pubmed: [24639404](https://pubmed.ncbi.nlm.nih.gov/24639404/).
31. King TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. *Am J Respir Crit Care Med.* 2001; 164(6): 1025–1032, doi: [10.1164/ajrccm.164.6.2001056](https://doi.org/10.1164/ajrccm.164.6.2001056), indexed in Pubmed: [11587991](https://pubmed.ncbi.nlm.nih.gov/11587991/).
32. Bartis D, Mise N, Mahida RY, et al. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? *Thorax.* 2014; 69(8): 760–765, doi: [10.1136/thoraxjnl-2013-204608](https://doi.org/10.1136/thoraxjnl-2013-204608), indexed in Pubmed: [24334519](https://pubmed.ncbi.nlm.nih.gov/24334519/).
33. Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. *Annu Rev Physiol.* 2011; 73: 413–435, doi: [10.1146/annurev-physiol-012110-142225](https://doi.org/10.1146/annurev-physiol-012110-142225), indexed in Pubmed: [21054168](https://pubmed.ncbi.nlm.nih.gov/21054168/).
34. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *J Clin Invest.* 2009; 119(6): 1420–1428, doi: [10.1172/JCI39104](https://doi.org/10.1172/JCI39104), indexed in Pubmed: [19487818](https://pubmed.ncbi.nlm.nih.gov/19487818/).

35. Yasui M, Miyazaki Y, Mitaka K, et al. Epithelial-mesenchymal transition in chronic hypersensitivity pneumonitis. *J Med Dent Sci.* 2012; 59(1): 29–41, indexed in Pubmed: [23896962](#).
36. Shi K, Jiang J, Ma T, et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. *Respir Physiol Neurobiol.* 2014; 190: 113–117, doi: [10.1016/j.resp.2013.09.011](#), indexed in Pubmed: [24140943](#).
37. Yang YC, Piek E, Zavadil J, et al. Hierarchical model of gene regulation by transforming growth factor beta. *Proc Natl Acad Sci U S A.* 2003; 100(18): 10269–10274, doi: [10.1073/pnas.1834070100](#), indexed in Pubmed: [12930890](#).
38. von Gersdorff G, Susztak K, Rezvani F, et al. Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. *J Biol Chem.* 2000; 275(15): 11320–11326, indexed in Pubmed: [10753944](#).
39. Ohashi N, Yamamoto T, Uchida C, et al. Transcriptional induction of Smurf2 ubiquitin ligase by TGF-beta. *FEBS Lett.* 2005; 579(12): 2557–2563, doi: [10.1016/j.febslet.2005.03.069](#), indexed in Pubmed: [15862290](#).
40. Zhao J, Crowe DL, Castillo C, et al. Smad7 is a TGF-beta-inducible attenuator of Smad2/3-mediated inhibition of embryonic lung morphogenesis. *Mech Dev.* 2000; 93(1-2): 71–81, indexed in Pubmed: [10781941](#).
41. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. *J Clin Invest.* 2012; 122(8): 2756–2762, doi: [10.1172/JCI60323](#), indexed in Pubmed: [22850886](#).
42. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. *FASEB J.* 2004; 18(7): 816–827, doi: [doi:10.1096/fj.03-1273rev](#).
43. Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. *Hepatology.* 2003; 38(4): 879–889, doi: [10.1053/jhep.2003.50384](#), indexed in Pubmed: [14512875](#).
44. Yoshida K, Matsuzaki K, Mori S, et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. *Am J Pathol.* 2005; 166(4): 1029–1039, indexed in Pubmed: [15793284](#).
45. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature.* 2003; 425(6958): 577–584, doi: [10.1038/nature02006](#), indexed in Pubmed: [14534577](#).
46. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. *FASEB J.* 1999; 13(13): 1774–1786, indexed in Pubmed: [10506580](#).
47. Abreu JG, Ketpura NI, Reversade B, et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. *Nat Cell Biol.* 2002; 4(8): 599–604, doi: [10.1038/ncb826](#), indexed in Pubmed: [12134160](#).
48. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? *Mol Genet Metab.* 2000; 71(1-2): 276–292, doi: [10.1006/mgme.2000.3059](#), indexed in Pubmed: [11001822](#).
49. Yu CC, Hsu MJ, Kuo ML, et al. Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway. *J Immunol.* 2009; 182(12): 7916–7927, doi: [10.4049/jimmunol.0801582](#), indexed in Pubmed: [19494316](#).
50. Ohnishi H, Oka T, Kusachi S, et al. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. *J Mol Cell Cardiol.* 1998; 30(11): 2411–2422, doi: [10.1006/jmcc.1998.0799](#), indexed in Pubmed: [9925376](#).
51. Kennedy L, Liu S, Shi-Wen Xu, et al. CCN2 is necessary for the function of mouse embryonic fibroblasts. *Exp Cell Res.* 2007; 313(5): 952–964, doi: [10.1016/j.yexcr.2006.12.006](#), indexed in Pubmed: [17239853](#).
52. Lasky JA, Ortiz LA, Tonthat B, et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. *Am J Physiol.* 1998; 275(2 Pt 1): L365–L371, indexed in Pubmed: [9700098](#).
53. Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. *Eur Respir J.* 2001; 17(6): 1220–1227, indexed in Pubmed: [11491168](#).
54. Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. *J Invest Dermatol.* 1996; 106(4): 729–733, indexed in Pubmed: [8618012](#).
55. Semenzato G, Adami F, Maschio N, et al. Immune mechanisms in interstitial lung diseases. *Allergy.* 2000; 55(12): 1103–1120, indexed in Pubmed: [11117267](#).
56. Panek M, Pietras T, Fabijan A, et al. The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients. *Inflammation.* 2015; 38(4): 1479–1492, doi: [10.1007/s10753-015-0123-3](#), indexed in Pubmed: [25649164](#).
57. Nho RS, Xia H, Diebold D, et al. PTEN regulates fibroblast elimination during collagen matrix contraction. *J Biol Chem.* 2006; 281(44): 33291–33301, doi: [10.1074/jbc.M606450200](#), indexed in Pubmed: [16963781](#).
58. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol.* 2004; 20: 781–810, doi: [10.1146/annurev.cellbio.20.010403.113126](#), indexed in Pubmed: [15473860](#).
59. Mucenski ML, Wert SE, Nation JM, et al. beta-Catenin is required for specification of proximal/distal cell fate during lung morphogenesis. *J Biol Chem.* 2003; 278(41): 40231–40238, doi: [10.1074/jbc.M305892200](#), indexed in Pubmed: [12885771](#).
60. Shu W, Guttentag S, Wang Z, et al. Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. *Dev Biol.* 2005; 283(1): 226–239, doi: [10.1016/j.ydbio.2005.04.014](#), indexed in Pubmed: [15907834](#).
61. Chilosi M, Poletti V, Zamò A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. *Am J Pathol.* 2003; 162(5): 1495–1502, indexed in Pubmed: [12707032](#).
62. Cheon SS, Nadesan P, Poon R, et al. Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. *Exp Cell Res.* 2004; 293(2): 267–274, indexed in Pubmed: [14729464](#).
63. Morali OG, Delmas V, Moore R, et al. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. *Oncogene.* 2001; 20(36): 4942–4950, doi: [10.1038/sj.onc.1204660](#), indexed in Pubmed: [11526479](#).
64. Königshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. *PLoS One.* 2008; 3(5): e2142, doi: [10.1371/journal.pone.0002142](#), indexed in Pubmed: [18478089](#).
65. Lam AP, Flozak AS, Russell S, et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. *Am J Respir Cell Mol Biol.* 2011; 45(5): 915–922, doi: [10.1165/rcmb.2010-0113OC](#), indexed in Pubmed: [21454805](#).
66. Caraci F, Gili E, Calafiore M, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. *Pharmacol Res.* 2008; 57(4): 274–282, doi: [10.1016/j.phrs.2008.02.001](#), indexed in Pubmed: [18346908](#).
67. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol.* 2009; 9(8): 581–593, doi: [10.1038/nri2567](#), indexed in Pubmed: [19498381](#).
68. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. *Proc Natl Acad Sci U S A.* 2010; 107(14): 6328–6333, doi: [10.1073/pnas.0914843107](#), indexed in Pubmed: [20304794](#).
69. Zeng Y. Principles of micro-RNA production and maturation. *Oncogene.* 2006; 25(46): 6156–6162, doi: [10.1038/sj.onc.1209908](#), indexed in Pubmed: [17028594](#).
70. Tomankova T, Petrek M, Kriegova E. Involvement of microRNAs in physiological and pathological processes in the lung. *Respir Res.* 2010; 11: 159, doi: [10.1186/1465-9921-11-159](#), indexed in Pubmed: [21092244](#).
71. Perry MM, Moschos SA, Williams AE, et al. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. *J Immunol.* 2008; 180(8): 5689–5698, indexed in Pubmed: [18390754](#).

72. Banerjee A, Schambach F, DeJong CS, et al. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. *Eur J Immunol*. 2010; 40(1): 225–231, doi: [10.1002/eji.200939381](https://doi.org/10.1002/eji.200939381), indexed in Pubmed: [19877012](https://pubmed.ncbi.nlm.nih.gov/19877012/).
73. Izzotti A, Calin GA, Steele VE, et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. *FASEB J*. 2009; 23(3): 806–812, doi: [10.1096/fj.08-121384](https://doi.org/10.1096/fj.08-121384), indexed in Pubmed: [18952709](https://pubmed.ncbi.nlm.nih.gov/18952709/).
74. Imaizumi T, Tanaka H, Tajima A, et al. IFN- γ and TNF- α synergistically induce microRNA-155 which regulates TAB2/IP-10 expression in human mesangial cells. *Am J Nephrol*. 2010; 32(5): 462–468, doi: [10.1159/000321365](https://doi.org/10.1159/000321365), indexed in Pubmed: [20948191](https://pubmed.ncbi.nlm.nih.gov/20948191/).
75. Xiao X, Huang C, Zhao C, et al. Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. *Arch Biochem Biophys*. 2015; 566: 49–57, doi: [10.1016/j.abb.2014.12.007](https://doi.org/10.1016/j.abb.2014.12.007), indexed in Pubmed: [25524739](https://pubmed.ncbi.nlm.nih.gov/25524739/).
76. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2010; 182(2): 220–229, doi: [10.1164/rccm.200911-1698OC](https://doi.org/10.1164/rccm.200911-1698OC), indexed in Pubmed: [20395557](https://pubmed.ncbi.nlm.nih.gov/20395557/).
77. Das S, Kumar M, Negi V, et al. MicroRNA-326 regulates profibrotic functions of transforming growth factor- β in pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2014; 50(5): 882–892, doi: [10.1165/rcmb.2013-0195OC](https://doi.org/10.1165/rcmb.2013-0195OC), indexed in Pubmed: [24279830](https://pubmed.ncbi.nlm.nih.gov/24279830/).
78. Milosevic J, Pandit K, Magister M, et al. Profibrotic role of miR-154 in pulmonary fibrosis. *Am J Respir Cell Mol Biol*. 2012; 47(6): 879–887, doi: [10.1165/rcmb.2011-0377OC](https://doi.org/10.1165/rcmb.2011-0377OC), indexed in Pubmed: [23043088](https://pubmed.ncbi.nlm.nih.gov/23043088/).
79. Wang Y, Huang C, Reddy Chintagari N, et al. miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt/ β -catenin pathway. *Nucleic Acids Res*. 2013; 41(6): 3833–3844, doi: [10.1093/nar/gks1460](https://doi.org/10.1093/nar/gks1460), indexed in Pubmed: [23396279](https://pubmed.ncbi.nlm.nih.gov/23396279/).
80. Lino Cardenas CL, Henaoui IS, Courcot E, et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGF β -induced lung fibroblast activation by targeting caveolin-1. *PLoS Genet*. 2013; 9(2): e1003291, doi: [10.1371/journal.pgen.1003291](https://doi.org/10.1371/journal.pgen.1003291), indexed in Pubmed: [23459460](https://pubmed.ncbi.nlm.nih.gov/23459460/).
81. Pottier N, Maurin T, Chevalier B, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. *PLoS One*. 2009; 4(8): e6718, doi: [10.1371/journal.pone.0006718](https://doi.org/10.1371/journal.pone.0006718), indexed in Pubmed: [19701459](https://pubmed.ncbi.nlm.nih.gov/19701459/).
82. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. *J Exp Med*. 2010; 207(8): 1589–1597, doi: [10.1084/jem.20100035](https://doi.org/10.1084/jem.20100035), indexed in Pubmed: [20643828](https://pubmed.ncbi.nlm.nih.gov/20643828/).
83. Marquez RT, Wendlandt E, Galle CS, et al. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. *Am J Physiol Gastrointest Liver Physiol*. 2010; 298(4): G535–G541, doi: [10.1152/ajpgi.00338.2009](https://doi.org/10.1152/ajpgi.00338.2009), indexed in Pubmed: [20167875](https://pubmed.ncbi.nlm.nih.gov/20167875/).
84. Dakhllallah D, Batte K, Wang Y, et al. Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. *Am J Respir Crit Care Med*. 2013; 187(4): 397–405, doi: [10.1164/rccm.201205-0888OC](https://doi.org/10.1164/rccm.201205-0888OC), indexed in Pubmed: [23306545](https://pubmed.ncbi.nlm.nih.gov/23306545/).
85. Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. *Cancer Res*. 2008; 68(19): 7846–7854, doi: [10.1158/0008-5472.CAN-08-1942](https://doi.org/10.1158/0008-5472.CAN-08-1942), indexed in Pubmed: [18829540](https://pubmed.ncbi.nlm.nih.gov/18829540/).
86. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol*. 2008; 10(5): 593–601, doi: [10.1038/ncb1722](https://doi.org/10.1038/ncb1722), indexed in Pubmed: [18376396](https://pubmed.ncbi.nlm.nih.gov/18376396/).